First North Announcement no. 6 2007/ 27th April, 2007
Copenhagen, 27th April, 2007
Summary: Quarterly Announcement - Aresa has begun the first growth trials and
new test sites are being prepared for use.
Quarterly Announcement, 1st Quarter 2007
The plant biotech company Aresa has used the first months of the year to prepare
the multitude of seeding and growth tests that are planned for the growth season
2007.
Aresa has entered into a collaboration with the Danish Defence for the use of a
3.000m² test field at their site in Jægerspris. This site is to substitute the
previous test site at Amager. The new test site in Jægerspris is being
established and gives Aresa a larger and better area for testing in 2007 and
beyond.
The first growth tests have been initiated and activities will continue
throughout the growing season 2007.
Aresa has, during the first quarter, applied for GMO approval for testing in
both Denmark and in Bosnia-Herzegovina. The process in Denmark is ongoing and an
approval is expected soon. In Bosnia-Herzegovina, Aresa has received a rejection
of the GMO application and as a consequence of this, initial discussion has been
initiated with the neighbouring country Serbia to establish a test area there.
Serbia has since 2001 had GMO legislation in place and the necessary formal
structures therefore exists to properly deal with GMO applications.
On the 21st March Aresa received notification that the patent authorities in
South Africa and in Singapore had granted a patent in respect of “Reporter
system for plants”, patent No. 2004/9782 in South Africa and patent No. 108113
in Singapore (see First North announcement No. 5 2007).
Aresa's first General Assembly, after the introduction on First North, was held
on the 15th March. The Supervisory Board was re-elected and the Annual Report
for 2006 was approved.
The unaudited financial figures for the period 1st January to 31st March 2007
are as follows:
--------------------------------------------------------------------------------
| (amounts in '000 DKK) | 1/1 - 31/3 2007 | 1/1 - 31/3 2006 |
--------------------------------------------------------------------------------
| Net turnover | 0 | 0 |
--------------------------------------------------------------------------------
| Result of Operations | -3,837 | -2,130 |
--------------------------------------------------------------------------------
| Financials, net | 297 | 143 |
--------------------------------------------------------------------------------
| Result before tax | -3,540 | -1,987 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| (amounts in '000 DKK) | 1/1 - 30/9 2006 | 1/1 - 30/9 2005 |
--------------------------------------------------------------------------------
| Assets, total | 51,543 | 64,445 |
--------------------------------------------------------------------------------
| Equity, total | 49,464 | 62,791 |
--------------------------------------------------------------------------------
Development of equity ('000 DKK):
Equity 1/1 2007: 53,004
Net result first quarter -3.540
Equity 31/3 2007: 49,464
For the full year a negative net result of DKK 14-17 million is expected, which
is in accordance with previously communicated expectations.
Best regards,
Jarne Elleholm
CEO
Aresa A/S
Further information can be obtained by contacting Jarne Elleholm, CEO for Aresa
A/S on +45 70227747, mobile: +45 41190136 or to the company's financial advisor
HSH Gudme Corporate Finance A/S, Morten Kjærulff, Director, +45 33449431.
About Aresa
Aresa is a plant biotech company established in 2001 by the company's current
CSO, Carsten Meier and has origins from the Institute of Molecular Biology at
Copenhagen University.
Aresa has developed two plant based technology platforms, BioSensor for the
detection of substances in soil, hereunder evaporation of explosives from
landmines; and BioPharma, a tool for the optimisation and production of
antibodies and proteins in plants.
Aresa was listed on the Copenhagen OMX-First North market place in 2006. Aresa
is based at Symbion Science Park in Copenhagen and has greenhouse facilities in
the outskirts of Copenhagen and test areas in Denmark, Croatia and in Bosnia
Herzegovina. Aresa has 17 employees, hereof 9 within research and development
and 5 within landmine operations.
Quarterly Announcement - Aresa has begun the first growth trials and new test sites are being prepared for use.
| Source: Aqualife A/S
Attachments
